Skip to main content
Medical information Clinical review pending

Genetic Testing

DMD Mutation Screening 79 Exons Prenatal

Prenatal genetic test to detect mutations in the dystrophin gene associated with Duchenne muscular dystrophy (DMD). Helps expectant parents understand risks for early management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Confirm with the laboratory before booking.
Results
Typically 7-10 days. Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking.
Test priceKSh 52,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the DMD Mutation Screening 79 Exons Prenatal test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Expectant parents with a family history of DMD.
  • ✓Known carriers of dystrophin gene mutations.
  • ✓Previous child diagnosed with DMD.
  • ✓Concerns about genetic risk for DMD in the fetus.
02

In plain language

What this test helps you understand

Detects mutations in the dystrophin gene associated with Duchenne muscular dystrophy (DMD) during pregnancy. Provides information for family planning and potential early management strategies.
The DMD Mutation Screening 79 Exons Prenatal test is a genetic diagnostic tool used to identify mutations in the dystrophin gene, which cause Duchenne muscular dystrophy (DMD). DMD primarily affects males, leading to progressive muscle weakness. This prenatal test is designed for expectant parents concerned about the risk of DMD in their child.

This test analyzes 79 exons of the dystrophin gene, providing a comprehensive screening for mutations linked to DMD. Identifying these mutations allows healthcare providers to assess the risk and plan for appropriate care if needed.

This test is recommended for expectant parents with a family history of DMD, known carriers of dystrophin gene mutations, or those with concerns about genetic disorders in their family. Early detection enables informed family planning and access to specialized care and management options for the child if diagnosed.

Results are typically available within 7-10 days. A positive result indicates the presence of a mutation associated with DMD, while a negative result suggests no detectable mutations within the tested exons. Discussing the results with a healthcare provider is crucial for understanding their implications.

To book this test, please contact us at +254711564616. A doctor's prescription is required for this test, but specific conditions apply regarding surgery, pregnancy, and travel abroad. Confirm details with the laboratory before booking.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking.
SampleConfirm with the laboratory before booking.
MethodologyConfirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test screens for mutations in 79 exons of the dystrophin gene. It may not detect all possible mutations associated with DMD. A negative result does not completely rule out the condition. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

DMD is a genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting males.
Expectant parents with a family history of DMD, known carriers, or those with concerns about the genetic risk should consider this test.
A positive result indicates the presence of a mutation associated with DMD in the fetus. Further consultation with a healthcare provider is necessary.
Yes, a doctor's prescription is required for this test. Specific conditions apply regarding surgery, pregnancy, and travel abroad.
The test analyzes 79 exons, providing comprehensive screening. However, it may not detect all possible mutations. Discuss limitations with your doctor.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp